Indication

As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of

  • ≥30 kg/m² (obese), or
  • ≥27 kg/m² to <30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.

Medicine details

Medicine name:
liraglutide (Saxenda)
SMC ID:
SMC2378
Pharmaceutical company
Novo Nordisk Ltd
BNF chapter
Endocrine system
Submission type
Full
Publication due date:
11 October 2021
SMC meeting date:
07 September 2021
Patient group submission deadline:
02 August 2021